Society guideline links: Pleural mesothelioma

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022)

●National Cancer Institute (NCI) Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer (IASLC), and Mesothelioma Applied Research Foundation (Meso Foundation): Consensus statement on radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials (2018)

Canada

●Cancer Care Ontario (CCO): Endorsement of the 2018 American Society of Clinical Oncology (ASCO) treatment of malignant pleural mesothelioma guideline (2018)

United States

●American Society of Clinical Oncology (ASCO): Treatment of malignant pleural mesothelioma – Clinical practice guideline (2018)

●National Cancer Institute (NCI) Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer (IASLC), and Mesothelioma Applied Research Foundation (Meso Foundation): Consensus statement on radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials (2018)

Europe

●European Society for Medical Oncology (ESMO): Malignant pleural mesothelioma – Clinical practice guidelines for diagnosis, treatment, and follow-up (2021)

●European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO): Guidelines for the management of malignant pleural mesothelioma (2020)

●ERS/EACTS: Statement on the management of malignant pleural effusions (2018)

United Kingdom

●National Institute for Health and Care Excellence): Technology appraisal guidance on nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (2022)

●British Thoracic Society (BTS): Guideline for the investigation and management of malignant pleural mesothelioma (2018)